" Drug Development and Scleroderma"
Richard Silver, MD

Annual Research Forum,
New York, NY
November 14, 2015

About Dr. Silver:


Richard M. Silver, M.D. graduated from Vanderbilt University School of Medicine and completed training in Internal Medicine at the University of North Carolina at Chapel Hill. He trained in Pediatric Rheumatology at London’s Northwick Park Hospital and in Adult Rheumatology at the University of California at San Diego. Dr. Silver joined the faculty of the Medical University of South Carolina in 1981, where he now holds the title of Distinguished University Professor. He serves as Director of the Division of Rheumatology and Vice-Chair for Development in the Department of Medicine.

Dr. Silver has devoted his professional career to the care and study of patients with scleroderma. He was among the first to characterize cells and proteins implicated in scleroderma lung disease. Dr. Silver’s pilot studies were instrumental in the inception of the Scleroderma Lung Study. In recent years, his group has provided insight into the biologic basis of racial disparities seen in scleroderma. He was also one of the first to recognize and describe patients with the eosinophilia myalgia syndrome. Dr. Silver has published more than 200 articles and chapters pertaining to scleroderma and has received national recognition for his clinical and teaching skills. In 2007, the MUSC Board of Trustees named him a “Master Teacher.” Dr. Silver has trained more than 75 rheumatology fellows, many of whom hold academic positions and practice rheumatology in 24 states and abroad.